The first of these was undertaken in patients with advanced NSCLC (n = 109) who received antibiotics (n = 20) either 1 month before, or within 1 month, of initiation of anti-PD-1-based therapy (89). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.